| Revision as of 09:49, 31 October 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').← Previous edit |
Latest revision as of 11:39, 20 September 2024 edit undoInternetArchiveBot (talk | contribs)Bots, Pending changes reviewers5,384,417 edits Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5 |
| (27 intermediate revisions by 19 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 450071674 |
|
| verifiedrevid = 458270653 |
|
| type = mab |
|
| type = mab |
|
| image = |
|
| image = |
|
| alt = |
|
| alt = |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu |
|
| source = zu |
|
| target = ] |
|
| target = ] |
|
<!--Clinical data--> |
|
<!--Clinical data --> |
|
| tradename = |
|
| tradename = Alzumab |
|
| Drugs.com = |
|
| Drugs.com = |
|
| MedlinePlus = |
|
| MedlinePlus = |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category= |
|
| pregnancy_category= |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_status = |
|
| legal_status = Approved in India |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
|
|
| bioavailability = |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
| metabolism = |
|
| excretion = |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| excretion = |
|
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|changed|CAS}} |
|
| CAS_number = <!-- blanked - oldvalue: 1116433-11-4 --> |
|
| CAS_number = 1116433-11-4 |
| ⚫ |
| ATC_prefix = none |
|
| ⚫ |
| ATC_suffix = |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII = XQQ2RHV14N |
|
| UNII = XQQ2RHV14N |
|
| PubChem = |
|
| ATC_prefix = none |
|
⚫ |
| ATC_suffix = |
|
⚫ |
| PubChem = |
|
⚫ |
| KEGG = D12426 |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
|
| chemical_formula = |
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| molecular_weight = |
|
| molecular_weight = |
|
|
|
|
|
|
}} |
|
}} |
|
|
|
|
|
|
'''Itolizumab''' (], trade name '''Alzumab''') is a 'first in class' humanized IgG1 ] developed by ]<ref name=jayaraman2013>{{cite news | vauthors = Jayaramun K | title=Biocon's first-in-class anti-CD6 mAb reaches the market | date=December 2013 | pages=1062–3 | volume=31 | issue=12 | work=] | location=United Kingdom | url=http://www.nature.com/nbt/journal/v31/n12/full/nbt1213-1062b.html }}{{closed access}}</ref> and the ] (CIM), Havana.<ref>{{Cite web|url=https://theprint.in/health/india-prepares-to-test-itolizumab-the-drug-credited-for-lowering-covid-mortality-in-cuba/431666/|title=India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba|date=May 30, 2020}}</ref> |
|
'''Itolizumab''' is an immunomodulator. It binds to ].<ref>{{cite journal | author = ] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}</ref> |
|
|
|
|
|
|
== Mechanism of action == |
|
|
It selectively targets ], a pan ] marker involved in ], adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory ]s and possibly plays an important role by reducing T cell infiltration at sites of inflammation.<ref>{{cite web | title = Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis | url = http://www.biocon.com/docs/PR_080113.pdf?subLink=news | date = 8 January 2013 | publisher = Biocon Limited }}</ref> |
|
|
|
|
|
== Clinical trials == |
|
|
A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (]) score after 12 weeks of treatment in patients with moderate to severe ] compared to placebo.<ref>{{Cite web|url=https://www.thehindubusinessline.com/companies/biocons-test-shows-positive-results-for-itolizumab/article23068151.ece|title=Biocon's test shows positive results for Itolizumab | vauthors = Urs A |website=@businessline|date=10 January 2012 }}</ref> |
|
|
|
|
|
== Applications == |
|
|
Biocon received marketing authorization for the drug from the ] (DCGI) in January 2013 and marketing within India commenced in August 2013.<ref name="jayaraman2013" /><ref>{{cite news | title=Biocon's psoriasis drug, Itolizumab receives DCGI marketing authorization | date=January 8, 2013 | work=Pharmabiz.com | publisher=Saffron Media | location=India | url=http://www.pharmabiz.com/NewsDetails.aspx?aid=73075&sid=2 | access-date=January 10, 2013 | archive-date=February 19, 2017 | archive-url=https://web.archive.org/web/20170219170401/http://www.pharmabiz.com/NewsDetails.aspx?aid=73075&sid=2 | url-status=dead }}</ref> |
|
|
|
|
|
In July 2020, Biocon received authorization in India for its use in the treatment of ].<ref>{{Cite web |title=Biocon's Itolizumab approved for COVID-19 treatment: All you need to know |url= https://economictimes.indiatimes.com/industry/healthcare/biotech/biocons-itolizumab-approved-for-covid-19-treatment-all-you-need-to-know/videoshow/76943684.cms |access-date=2020-07-14 |website=The Economic Times}}</ref> |
|
|
|
|
|
== References == |
|
== References == |
|
<references/> |
|
<references /> |
|
|
|
|
|
{{monoclonals for immune system}} |
|
{{monoclonals for immune system}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|